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ABSTRACT 
 
Objective: A comparative evaluation of topical lysostaphin therapy with vancomycin and azithromycin in 
methicillin-resistant Staphylococcus aureus (MRSA) keratitis in a rabbit model. Methods: This study was conducted 
on 18 eyes of 18 rabbits. All rabbits were divided into 3 groups with 6 rabbits each. Right eyes were experimental 
eyes. Keratitis was induced by aseptically injecting the corneal stroma with 100 colony forming unit (CFU) of 
MRSA strain (MU-50). Each group was treated 5 hours post injection with one drop of 5% vancomycin, 0.28% 
lysostaphin or 1% azythromycin, every half an hour for 5 hours. Seven ocular parameters (conjunctival injection, 
chemosis, corneal infiltrate, corneal edema, flare in the anterior chamber, hypopyon formation, and iritis) were 
graded on a scale of 0 to 4 on slit lamp examination of rabbit eyes. Rabbits were sacrificed and corneas were excised 
and cultured to determine the number of CFU per cornea. Results: Lysostaphin significantly lowered the total slit 
lamp examination scoring of the experimental eye as compared to vancomycin and azithromycin (p-value 0.014) 
group. None of the eyes treated with vancomycin and azithromycin were sterile whereas four out of six eyes became 
sterile in lysostaphin treated group. There was significant lowering of mean log CFU/cornea in lysostaphin group as 
compared to vancomycin and azithromycin (p-value 0.008). Also, there was no statistically significant difference in 
slit lamp examination scoring between vancomycin and azithromycin groups. Conclusion: Lysostaphin has a greater 
potency to treat methicillin-resistant Staphylococcus aureus induced keratitis as compared to azithromycin and 
vancomycin. 
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Introduction  
 
Bacterial keratitis is one of the leading causes of 
monocular disability in the developing world. Amongst 
different bacterial species, Staphylococcus aureusis a 
prevalent cause of bacterial keratitis, especiallyamong 
individuals with a previously compromised cornea[1-
4].Topical cefazolin often used in combination with an 
aminoglycoside or a fluoroquinoloneare the antibiotics 
most often prescribed for treating Staphylococcus 
keratitis[5-8]. At present the antibioticof choice for 
treatment of Methicillin-resistant Staphylococcus 
aureus(MRSA) keratitis is vancomycin,but 
accumulating mutations in Staphylococcusaureus have 
led to resistance to vancomycin[9-12]. The continuing 
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emergence of antibiotic-resistant Staphylococcus 
aureus infections has spurred the need for new 
antimicrobial agents to treat these infections. 
Lysostaphin is a potent anti-staphylococcal agent and 
has potential as a therapeutic agent against 
Staphylococcus aureus infections[13, 14]. Lysostaphin 
has not yet been approved as a therapy for 
staphylococcus keratitis.The present study is aimed at 
investigating topical lysostaphin therapy with recently 
introduced antibacterial antibiotics viz. vancomycin 
and azithromycin in MRSA induced keratitis in rabbits.  
 
Material and method 
 
The present study was conducted on 18 eyes of 18 
rabbits at the Institute of Ophthalmology, JNMC, 
AMU, Aligarh, after obtaining the ethical clearance 
from the animal house of JNMC. No author has 
financial interest in this study or the product. 
Equipment used: (1) tissue Homogeniser- employed for 
homogenising the cornea during its processing. (2) 
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Laminar flow bench- based on work principle 
involving double filtration of air. (3) 
Spectrophotometer. (4) Slit Lamp Biomicroscope 
Lysostaphin (Sigma Aldrich, Germany) is a protein 
complex with highly specific lytic activity against 
staphylococcus species and it is produced by 
recombinant technology by expressing it in E coli. It is 
supplied in the form of lyophilized powder with 
activity of >3000 unit/mg of solid in 5mg vial, shipped 
in dry ice & stored at a temperature of 20°C.  
Culture used: nutrient agar, nutrient broth, human 
blood agar, saline solution 0.85%.  
Drug used: vancomycin hydrochloride, lysostaphin, 
azithromycin,proparacaine hydrochloride, ketamine 
hydrochloride injection. 
MRSA strains Mu 50 employed in the present study 
were kindly provided by Prof. Keiichi Hiramatsu and 
his team of Prof. Teruyo Ito, Juntendo University, 
Tokyo, Japan.  
Albino rabbits, Oryctolaguscuniculus, of both sexes 
were used. Rabbits were divided into 3 groups (Group 
A, B and C). These groups comprised of 6 rabbits in 
each. Right eyes (RE) were used as experimental eyes. 
They were sedated by i.m injection of ketamine (22.5 
mg/kg).Keratitis was induced by aseptically injecting 
the corneal stroma with 100 colony forming unit (CFU) 
of given MRSA strain (per 10µl) with 1ml syringe 
having 30 gauge hypodermic needle[6](figure 1). Five 
hours post injection, all rabbits developed keratitis. 
Group A, B and C were treated by with one drop (45µl) 
of topical vancomycin(5.0%), lysostaphin(0.28%) and 
azythromycin(1%) dropsrespectively, every half an 
hour for 5 hours.The results were compared 10 hours 
post injection in terms ofslit lamp examination scoring 
of rabbit’s eyes(Table 1,figure 2) and CFU of 
Staphylococcus aureusper cornea. This methodology 
was adapted from the work of Dajcset al, (2000) with 
minor modifications[15]. 
  
Table 1: Slit Lamp Biomicroscopy Scoring of Rabbit’s Eyes 
  
S.no Parameters Grades 
Grade 0 no change. 
1)  CONGESTION OF 
CONJUNCTIVA 
1-Flushed reddish, slight perilimbal injection in1quadrant. 
2-Bright red, 2 quadrants. 
3-Dark beefy red, 3 quadrants. 
4-Diffuse congestion all around. 
2)  CHEMOSIS  OF 
CONJUNCTIVA 
1-Swelling above normal, no lid eversion. 
2-Swelling with   misalignment of lids upper>lower. 
3-Swelling with partial eversion, upper=lower. 
4-Marked eversion, Upper>lower. 
3)  CORNEAL INFILTRATES 1-Only upto epithelial surface. 
2-May be dense but superficial and limited to ulcer base. 
3-Dense infiltrates extending to mid stroma. 
4-Dense extending deeper than mid stroma / upto sclera. 
4)  CORNEAL  EDEMA 
 
1-Striped change of cornea. 
2-Limited corneal edema. 
3-Obvious corneal edema. 
4-Diffuse corneal edema. 
5)  FLARE 1-Faint barely detectable. 
2-Moderate, iris and lens details clear. 
3-Marked, iris and lens details hazy. 
4-Intense flare, fibrinousexudate. 
6)  HYPOPYON 1-Upto 1 mm. 
2-More than 1 - 2 mm. 
3-More than 2 – 3 mm. 
4-More than 3 mm. 
7)  IRITIS 1-Slight congestion of iris vessels, only part of iris. 
2-Mild congestion, all vessels of iris involved. 
3-Moderate congestion, all vessels of iris involved. 
4-Marked congestion, all vessels, little normal tissue. 
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Each of seven ocular parameters (conjunctival 
injection, chemosis, corneal infiltrate, corneal edema, 
flare in the anterior chamber, hypopyon formation and 
iritis) were graded on a scale of 0 to 4. The parameter 
grades were added to produce a single total slit lamp 
examination score ranging from 0 (normal eye) to 28 
(maximally inflamed eye)[6]. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
The data was analysed by paired t-test, p-values of ≤ 
0.05 were considered significant. 
Results and observations 
Slit lamp examination scoring 
During the course of study, topical use of lysostaphin 
treated group showed significantly lower total slit lamp 
examination scoring as compared tovancomycin group 
(p-value 0.015) and azithromycin group (p-value 
0.014) (Table 2 and Figure3). Lysostaphin significantly 
lowered slit lamp examination scoring in three out of 
the seven parameters studied in the present study viz. 
corneal infiltrate, corneal edema and flare. (Figure 4-6) 
 
Table 2 &Figure 3: Total score - Slit Lamp 
Examination scoring after 10 hours post injection with 
100 colony forming units of bacterial test strain 
Methicillin-Resistant Staphylococcus aureus Mu-50. 
 
 
Figure 3:Total slit lamp examination scoring 
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Figure 1: Intrastromal injection of MRSA 
strain in rabbit cornea to induce keratitis 
Figure 2: Slit lamp examination of rabbit 
eye 
 Asian Pac. J. Health Sci., 2015; 2(2): 105-112                                           e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________
Soni et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(2): 105-112 
www.apjhs.com      108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Corneal Infiltrates- Slit Lamp Examination Scoring after 10 hours post injection with 100 colony  
forming units of bacterial test strain Methicillin-Resistant StaphylococcusaureusMu-50. 
 
 
 
Figure 5:Corneal Edema- Slit Lamp Examination Scoring after 10 hours post injection with 100 colony 
forming units of bacterial test strain Methicillin-Resistant Staphylococcus aureus Mu-50. 
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Figure 6:Flare- Slit Lamp Examination Scoring after 10 hours post injection with 100 colonyforming units of 
bacterial test strain Methicillin-Resistant Staphylococcus aureusMu-50. 
 
 
Microbiological evaluation 
 
Lysostaphin lowered mean log colony forming 
units/cornea in experimental eye to 0.6666 ± 1.0327 
which was statistically highly significant (p-value 
0.008) as compared to vancomycin (mean log colony 
forming units/Cornea of 2.4761 ± 0.2157) group and  
azithromycin (mean log colony forming units/Cornea 
of 2.5131 ± 0.1834) group with p-value 0.008. 
Vancomycin and azithromycin treated eyes were 
having insignificant difference amongst them with p-
value being 0.798 as shown in Table 3.None of the 
eyes treated with vancomycin and azithromycin were 
sterile whereas four out of six eyes became sterile in 
lysostaphin treated group. 
 
 
Table 3:Antibacterial effect of Antibiotics on Methicillin-Resistant Staphylococcus aureus induced keratitis 
 
 
 
 
S.NO. 
 
 
 
Experimental 
Animal 
Colony Forming Units Obtained 
Vancomycin Lysostaphin Azithromycin 
Colony 
forming 
units/ 
Cornea 
Log colony 
forming 
units/ 
Cornea 
Colony 
forming 
units/ 
Cornea 
Log colony 
forming units/ 
Cornea 
Colony 
forming 
units/ 
Cornea 
Log 
colony 
forming 
units/ 
Cornea 
1. RABBIT 1 200 2.3010 0 0.0000 300 2.4771 
2. RABBIT 2 300 2.4771 0 0.0000 200 2.3010 
3. RABBIT 3 200 2.3010 0 0.0000 500 2.6989 
4. RABBIT 4 500 2.6989 100 2.0000 200 2.3010 
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5. RABBIT 5 600 2.7781 0 0.0000 400 2.6020 
6. RABBIT 6 200 2.3010 100 2.0000 500 2.6989 
 
Discussion 
 
Bacterial keratitis, because of its high morbidity and 
potential complications, is amongst one ofthe most 
vision threatening infectious ocular pathologies. The 
treatment of keratitis continues to pose challenge to the 
ophthalmologists and the issue gets further complicated 
if the infection is caused by multidrug resistant 
superbug like methicillin-resistant Staphylococcus 
aureus(MRSA).Lysostaphin has been shown to be a 
potent antibacterial therapy for treatment of many 
infections e.g. keratitis [15] and endophthalmitis[16-
18] produced by experimental MRSA infection in 
rabbits.Lysostaphin appears to be more effective than 
any other drug tested in the treatment of experimental 
S. aureus keratitis[19, 20]Keeping in the view the 
potential uses of lysostaphin, experimental models of 
MRSA keratitis were developed in the present study to 
further evaluate the efficacy of lysostaphin therapy 
relative to vancomycinand azithromycin. Lysostaphin 
seemed to have penetrated the intact corneal epithelium 
and lowered mean log CFU/cornea in experimental 
eyes which was statistically highly significant as 
compared to vancomycin and azithromycin. Our 
findings were in agreement with observations made 
bystudies done elsewhere, but the minor difference 
could be attributed to the virulence of the organism 
employed[15].In the present investigation lysostaphin 
could sterilize 66% of treated corneas as compared 
with vancomycin and azithromycin group where none 
of the corneas were sterile. This was again comparable 
to the findings of Dajcset al, (2000) who demonstrated 
that lysostaphin sterilized as much as 75% of treated 
cornea as compared with untreated group[15]. 
Lysostaphin rapidly lyses the MRSA in both static and 
log phase, leading to a drastic decrease in the log CFU 
counts[21]. However, vancomycin is a slow-acting 
antibiotic that has significant side effects like 
conjunctival inflammation and corneal edema[22, 23]. 
Topical use of azithromycin has been studied in the 
treatment of bacterial or trachomatous conjunctivitis 
[24]. But its antibacterial use in MRSAkeratitis along 
with its comparison with lysostaphin and vancomycin 
has not been well studied before. 
 
Conclusion 
 
On the basis of observations made in the present study 
topical lysostaphin is an effective novel strategy 
against methicillin- resistant Staphylococcus aureu 
skeratitis in rabbit models as compared to other 
antibiotics studied viz. vancomycin and azithromycin. 
However, its broad clinical applications needs 
standardization of drug formulation either alone or in 
combination with other antibiotics and they have to be 
validated in larger experimental studies and clinical 
trials before considering them safe for therapeutic uses 
in humans.  
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